"Advanced therapies in Neurodegeneration: Bridging Neuroscience, Bioengineering and Optogenetics" Symposium

by Christin Schülke

Due to COVID-19, the symposium had to be reorganized and will be held in the form of an online webinar on April 29 & 30, 2020. Registration is still open until the start of the event. The updated webinar program can be found here.

The Symposium on “Advanced therapies in Neurodegeneration: Bridging Neuroscience, Bioengineering and Optogenetics” is organized by the Early Stage Researchers of the Marie Skłodowska-Curie Actions Horizon 2020 project Training4CRM

The event is free of charge, funded by Horizon 2020, and will feature a lot of interesting talks about Neuroscience, Neurodegenerative diseases like Parkinson's Disease, Huntington's Disease and Epilepsy, Stem Cell Therapy, Bioengineering and Optogenetics. More information about the symposium can be found here: http://training4crm.com/symposium/

 

Speakers

Jenny Emnéus, Technical University of Denmark – European Network Training4CRM: Cell-based Regenerative Medicine for neurodegenerative diseases
Etienne Hirsch, ICM Paris – Why clinical trials fail in Parkinson disease
Ernest Arenas, Karolinska Institute – Cell replacement strategies for Parkinson’s disease: A single cell perspective. 
Juan Jose Toledo Aral, IBiS Sevilla – Neuroprotective Carotid Body Cell therapy in Parkinson’s Disease
Selina Wray, University College London – Patient-derived stem cell models of Alzheimer's disease and frontotemporal dementia
Cláudia Cavadas, University of Coimbra – Role of hypothalamus in aging / Caloric restriction to block neurodegenerative disease
Anne Rosser, Cardiff University – Taking stem cells towards the clinic for Huntington's disease
Mercé Masana, University of Barcelona – Huntington’s disease & Optogenetics 
My Andersson, Lund University – Epilepsy & Optogenetics 
Nigel Hooper, University of Manchester – Reverse engineering a human blood-brain barrier platform for studying neurovascular disease
Maria Joana Albuquerque Osório, Center for Translational Neuromedicine, University of 
Copenhagen – Cell and gene therapy for treatment of pediatric congenital disorders of myelin

We use a selection of our own and third-party cookies on the pages of this website: Essential cookies, which are required in order to use the website; functional cookies, which provide better easy of use when using the website; performance cookies, which we use to generate aggregated data on website use and statistics; and marketing cookies, which are used to display relevant content and advertising. If you choose "ACCEPT ALL", you consent to the use of all cookies. You can accept and reject individual cookie types and revoke your consent for the future at any time under "Settings".